Limited Validity of Mayo Endoscopic Subscore in Ulcerative Colitis with Concomitant Primary Sclerosing Cholangitis

Overview

Journal World J Gastrointest Endosc

Publisher Baishideng Publishing Group

Date 2024 Nov 27

PMID 39600557

Authors

Pavel Wohl

Alzbeta Krausova

Petr Wohl

Ondrej Fabian

Lukas Bajer

Jan Brezina

Pavel Drastich

Mojmir Hlavaty

Petra Novotna

Michal Kahle

Julius Spicak

Martin Gregor

Affiliations

Soon will be listed here.

Abstract

Background: Ulcerative colitis (UC) with concomitant primary sclerosing cholangitis (PSC) represents a distinct disease entity (PSC-UC). Mayo endoscopic subscore (MES) is a standard tool for assessing disease activity in UC but its relevance in PSC-UC remains unclear.

Aim: To assess the accuracy of MES in UC and PSC-UC patients, we performed histological scoring using Nancy histological index (NHI).

Methods: MES was assessed in 30 PSC-UC and 29 UC adult patients during endoscopy. NHI and inflammation were evaluated in biopsies from the cecum, rectum, and terminal ileum. In addition, perinuclear anti-neutrophil cytoplasmic antibodies, fecal calprotectin, body mass index, and other relevant clinical characteristics were collected.

Results: The median MES and NHI were similar for UC patients (MES grade 2 and NHI grade 2 in the rectum) but were different for PSC-UC patients (MES grade 0 and NHI grade 2 in the cecum). There was a correlation between MES and NHI for UC patients (Spearman's = 0.40, = 0.029) but not for PSC-UC patients. Histopathological examination revealed persistent microscopic inflammation in 88% of PSC-UC patients with MES grade 0 (46% of all PSC-UC patients). Moreover, MES overestimated the severity of active inflammation in an additional 11% of PSC-UC patients.

Conclusion: MES insufficiently identifies microscopic inflammation in PSC-UC. This indicates that histological evaluation should become a routine procedure of the diagnostic and grading system in both PSC-UC and PSC.

Citing Articles

Evaluation of Mayo endoscopic subscore in ulcerative colitis with concomitant primary sclerosing cholangitis.

Liu X, Sun X World J Gastrointest Endosc. 2025; 17(2):103448.

PMID: 39989857 PMC: 11843038. DOI: 10.4253/wjge.v17.i2.103448.

References

Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G . Development and validation of the Nancy histological index for UC. Gut. 2015; 66(1):43-49. DOI: 10.1136/gutjnl-2015-310187. View

Boonstra K, van Erpecum K, van Nieuwkerk K, Drenth J, Poen A, Witteman B . Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18(12):2270-6. DOI: 10.1002/ibd.22938. View

Sandborn W, Feagan B, Hanauer S, Lochs H, Lofberg R, Modigliani R . A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002; 122(2):512-30. DOI: 10.1053/gast.2002.31072. View

Mahmoud R, Shah S, Ten Hove J, Torres J, Mooiweer E, Castaneda D . No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2018; 156(5):1333-1344.e3. PMC: 7354096. DOI: 10.1053/j.gastro.2018.11.067. View

Lobaton T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G . The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015; 9(10):846-52. DOI: 10.1093/ecco-jcc/jjv111. View

Maaser C, Sturm A, Vavricka S, Kucharzik T, Fiorino G, Annese V . ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2018; 13(2):144-164. DOI: 10.1093/ecco-jcc/jjy113. View

Marchal-Bressenot A, Scherl A, Salleron J, Peyrin-Biroulet L . A practical guide to assess the Nancy histological index for UC. Gut. 2016; 65(11):1919-1920. PMC: 5099187. DOI: 10.1136/gutjnl-2016-312722. View

van Bokhorst Q, Houwen B, Hazewinkel Y, Fockens P, Dekker E . Advances in artificial intelligence and computer science for computer-aided diagnosis of colorectal polyps: current status. Endosc Int Open. 2023; 11(8):E752-E767. PMC: 10431975. DOI: 10.1055/a-2098-1999. View

Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A . ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. J Crohns Colitis. 2020; 14(11):1503-1511. DOI: 10.1093/ecco-jcc/jjaa110. View

10.

Fung B, Lindor K, Tabibian J . Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol. 2019; 25(6):659-671. PMC: 6378537. DOI: 10.3748/wjg.v25.i6.659. View

11.

Ozaki R, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A . Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. J Crohns Colitis. 2018; 12(11):1288-1294. DOI: 10.1093/ecco-jcc/jjy092. View

12.

Bouguen G, Levesque B, Pola S, Evans E, Sandborn W . Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2013; 20(2):231-9. DOI: 10.1097/01.MIB.0000437985.00190.aa. View

13.

Mohammed Vashist N, Samaan M, Mosli M, Parker C, MacDonald J, Nelson S . Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018; 1:CD011450. PMC: 6491285. DOI: 10.1002/14651858.CD011450.pub2. View

14.

Bjarnason I . The Use of Fecal Calprotectin in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2017; 13(1):53-56. PMC: 5390326. View

15.

Chapman R, Arborgh B, Rhodes J, Summerfield J, Dick R, Scheuer P . Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980; 21(10):870-7. PMC: 1419383. DOI: 10.1136/gut.21.10.870. View

16.

Ozawa T, Ishihara S, Fujishiro M, Kumagai Y, Shichijo S, Tada T . Automated endoscopic detection and classification of colorectal polyps using convolutional neural networks. Therap Adv Gastroenterol. 2020; 13:1756284820910659. PMC: 7092386. DOI: 10.1177/1756284820910659. View

17.

Park S, Abdi T, Gentry M, Laine L . Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis. Am J Gastroenterol. 2016; 111(12):1692-1701. DOI: 10.1038/ajg.2016.418. View

18.

Kornfeld D, Ekbom A, Ihre T . Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997; 41(4):522-5. PMC: 1891549. DOI: 10.1136/gut.41.4.522. View

19.

Weismuller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C . Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017; 152(8):1975-1984.e8. PMC: 5546611. DOI: 10.1053/j.gastro.2017.02.038. View

20.

Loftus Jr E, Sandborn W, Lindor K, Larusso N . Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis. 2013; 3(4):288-302. View